Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia

References

• LeuchtSBurkardTHendersonJMajMSartoriusNPhysical illness and schizophrenia: a review of the literatureActa Psychiatr Scand2007116531733317919153
   PubMed Web of Science ®Google Scholar
• SahaSChantDMcGrathJA systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?Arch Gen Psychiatry200764101123113117909124
   PubMed Web of Science ®Google Scholar
• BarnettAHMackinPChaudhryIMinimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemiaJ Psychopharmacol200721435737317656425
   PubMed Web of Science ®Google Scholar
• BrownSExcess mortality of schizophrenia. A meta-analysisBr J Psychiatry19971715025089519087
   PubMed Web of Science ®Google Scholar
• HennekensCHHennekensARHollarDCaseyDESchizophrenia and increased risks of cardiovascular diseaseAm Heart J200515061115112116338246
   PubMed Web of Science ®Google Scholar
• TranERouillonFLozeJYCancer mortality in patients with schizophrenia: an 11-year prospective cohort studyCancer2009115153555356219548261
   PubMed Web of Science ®Google Scholar
• MeyerJMDavisVGGoffDCChange in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Schizophr Res20081011327328618282690
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res201012323225233
   Web of Science ®Google Scholar
• De HertMCorrellCUBobesJPhysical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health careWorld Psychiatry2011101527721379357
   PubMed Web of Science ®Google Scholar
• NewcomerJWSecond generation (atypical) antipsychotics and metabolic effects. A comprehensive literature reviewCNS Drugs200519119315998156
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• De HertMSchreursVSweersKTypical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart reviewSchizophr Res20081011329530318282690
   PubMed Web of Science ®Google Scholar
• SmithMHopkinsDPevelerRCHoltRIWoodwardMIsmailKFirst- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysisBr J Psychiatry2008192640641118515889
   PubMed Web of Science ®Google Scholar
• DaumitGLGoffDCMeyerJMAntipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studySchizophr Res20081051317518718774696
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders 4th ed (DSM-IV)Washington, DCAmerican Psychiatric Association1994
   Google Scholar
• Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in a adults (Adult treatment panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIDanielsSRDiagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientifc StatementCirculation2005112172735275216157765
   PubMed Web of Science ®Google Scholar
• MajadasSOlivaresJGalanJDiezTPrevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophreniaCompr Psychiatry201253214515121621754
   PubMed Web of Science ®Google Scholar
• GiganteDPMouraECSardinhaLMPrevalence of overweight and obesity and associated factors, Brazil, 2006Rev Saude Publica200943Suppl 2S83S89
   Web of Science ®Google Scholar
• Leitão-AzevedoCLGuimarãesLRde AbreuMGGamaCSLobatoMIBelmonte-de-AbreuPSIncreased dyslipidemia in schizophrenic outpatients using new generation antipsychoticsRev Bras Psiquiatr200628430130417242810
   PubMed Web of Science ®Google Scholar
• TeixeiraPJRochaFLThe prevalence of metabolic syndrome among psychiatric inpatients in BrazilRev Bras Psiquiatr200729433033618200397
   PubMed Web of Science ®Google Scholar
• MisawaFShimizuKFujiiYIs antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional studyBMC Psychiatry201111118
   Google Scholar
• BakxJCvan den HoogenHJDeurenbergPvan DoremalenJvan den BoschWJChanges in serum total cholesterol levels over 18 years in a cohort of men and women: The Nijmegen Cohort StudyPrev Med200030213814510656841
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry1999156111686169610553730
   PubMed Web of Science ®Google Scholar
• MillenBACampbellGMBeasleyCMWeight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trialsJ Psychopharmacol201125563964520558497
   PubMed Web of Science ®Google Scholar
• PadmavatiRMcCreadieRGTirupatiSLow prevalence of obesity and metabolic syndrome in never-treated chronic schizophreniaSchizophr Res20101211319920220579855
   PubMed Web of Science ®Google Scholar
• De HertMCohenDBobesJPhysical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual levelWorld Psychiatry201110213815121633691
   PubMed Web of Science ®Google Scholar
• MitchellAJDelaffonVVancampfortDCorrellCUDe HertMGuideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practicesPsychol Med201242112514721846426
   PubMed Web of Science ®Google Scholar
• RatliffJCPalmeseLBReutenauerELLiskovEGriloCMTekCThe effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional studyCompr Psychiatry20125371028103322425530
   PubMed Web of Science ®Google Scholar
• VancampfortDProbstMKnapenJCarraroADe HertMAssociations between sedentary behaviour and metabolic parameters in patients with schizophreniaPsychiatry ResEpub4102012
   Google Scholar